Blocking CSF-1R with a CSF-1R tyrosine kinase inhibitor can reduce RCC proliferation and macrophage infiltration, which corresponds to a significant reduction in tumor volume (18–20). The gene discussed is CSF1R; the disease is renal cell carcinoma.